Chronic Pain and Medicinal Cannabis: How to Build an Effective Treatment Plan

Living with chronic pain is often less about a single moment of injury and more about the quiet, persistent way it settles into daily life. For those who have navigated the healthcare system for years, the search for relief can feel like a cycle of trying and discarding various options that either fall short or bring unwelcome side effects.

In Aotearoa New Zealand, the conversation around medicinal cannabis has shifted significantly since 2018. It is no longer a peripheral topic, but a structured clinical pathway for many of the one in five adults living with persistent discomfort. While it is not a first-line therapy, medicinal cannabis is increasingly recognised as a thoughtful addition to a treatment plan when conventional methods have not provided the support a person needs.

This guide explores how a treatment plan is built, starting with the biology of pain and moving into the practical, step-by-step nature of cannabinoid therapy.

Understanding the Landscape of Pain

Effective care begins with a simple but important realisation: not all pain is the same. To build a plan that feels sustainable, clinicians first look at the mechanism driving the symptoms.

Research generally groups chronic pain into three broad categories:

• Nociceptive Pain: This is the body’s natural response to tissue damage, such as a joint affected by osteoarthritis. It often feels like a localised ache or throb that follows a predictable pattern of movement.
• Inflammatory Pain: When the immune system stays on “high alert” after an injury or due to an autoimmune condition, it releases chemical mediators that sensitise nerve endings.
• Neuropathic Pain: This occurs when the nervous system itself is the source of the issue. People often describe this as burning, electric shocks, or “pins and needles.” It is a complex type of pain that frequently resists standard anti-inflammatory medications.

By identifying which of these mechanisms is most active, a clinician can tailor a plan that addresses the specific ways a person experiences their condition.

The Role of the Endocannabinoid System

The reason medicinal cannabis is discussed in clinical settings is due to a system we all have: the endocannabinoid system (ECS). Think of the ECS as a regulatory network that helps maintain balance, or homeostasis, across the body.

This system contains receptors (known as CB1 and CB2) located in the brain, the spinal cord, and on immune cells. They act much like a “volume knob” for pain signals. When the body’s natural levels of cannabinoids are unable to manage persistent pain, plant-derived cannabinoids like CBD and THC may be discussed to help supplement this system and restore a sense of balance.

THC and CBD: Finding the Right Balance

Medicinal cannabis is rarely about a single compound. Most effective plans involve a combination of the two primary cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which work together in what is often proposed as the “entourage effect.”

• CBD (Cannabidiol): This compound is non-intoxicating and is often the starting point for those new to this therapy. It is generally associated with managing inflammation and the anxiety that often accompanies long-term illness.
• THC (Tetrahydrocannabinol): THC is more directly analgesic. It can help alter the perception of pain at a spinal and cortical level, making discomfort feel less “bothersome” and allowing for better daily function.

Because everyone’s biology is unique, the ratio of these compounds is adjusted to find the “sweet spot” where a person feels relief without unwanted cognitive effects.

Building the Plan: Start Low, Go Slow

For a person who is already fatigued by their health journey, the idea of starting a new medication can feel daunting. This is why the clinical approach in New Zealand is intentionally gradual. It is often described as the “start low, go slow” philosophy.

Most plans follow a structured titration protocol:

1. The Starting Point: Many people begin with a low dose of CBD-dominant oil.
2. Incremental Changes: The dose is increased every few days. This allows the body to adjust and helps the patient feel in control of the process.
3. Regular Monitoring: A follow-up usually occurs within the first month to review how the symptoms are responding and to make any necessary adjustments to the timing or ratio.

Symptom Mapping and Practical Pacing

A sustainable plan is one that fits into a person’s actual life. Clinicians often use “symptom mapping” to decide when a dose should be taken. If a person finds that their pain peaks in the morning, the plan might prioritise a daytime CBD-heavy oil that supports movement without causing drowsiness. If sleep is the primary concern, a plan might include a small dose of THC in the evening to help improve sleep quality.

This approach validates the importance of rest and pacing. Medicinal cannabis is not a “quick fix” but a tool that, when used correctly, can help widen the window of what a person feels capable of doing each day.

Evaluating What “Working” Looks Like

In clinical trials, a “clinically important difference” is often defined as a 30 per cent reduction in pain intensity. While this number is a helpful benchmark for researchers, the real measure of success is often more personal.

Success might look like being able to walk to the end of the street, having the energy to cook a meal, or simply waking up feeling more restored. If no meaningful improvement is noticed after a trial period of four to twelve weeks, the plan is reviewed and either adjusted or stopped. This ensures that care remains responsible, safe, and focused on genuine quality of life.

A Path Forward with Support

Exploring medicinal cannabis is a collaborative process. It requires open dialogue between a patient and a clinician who understands the complexities of chronic conditions.

If you feel you have exhausted traditional pathways and would like to explore whether medicinal cannabis may be suitable for your situation, you can book a consultation with our team here.

We are here to walk beside you, providing clear information and compassionate support as you navigate the path toward reclaiming your well-being.

References

1. Stockings E, et al. Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: a systematic review and meta-analysis. Pain. 2018;159(10):1932-1954.
2. Goldberg, D. S., & McGee, S. J. (2011). Pain as a global public health priority. BMC public health, 11, 770. 
3. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2-S15.
4. Smart KM, et al. Mechanisms-based classifications of musculoskeletal pain: Part 1 of 3: Symptoms and signs of nociceptive pain in patients with low back (and leg) pain. Man Ther. 2012;17(4):336-344.
5. Kidd BL, Urban LA. Mechanisms of inflammatory pain. Br J Anaesth. 2001;87(1):3-11.
6. Colloca L, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002.
7. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516-525.
8. Bhaskar A, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021;3:22.
9. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.
10. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2(1):139-154.
11. Whiting PF, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473.
12. Orapharm. Medicinal cannabis prescribing guidelines for doctors in New Zealand. 2021.
13. Bhaskar A, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain. J Cannabis Res. 2021;3:22.
14. Farrar JT, et al. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage. 2003;25(5):406-411.